Human Complement Component 9, C9 ELISA Kit

Product Details

Customer Reviews and Q&A

Target Background

Name: Human Complement Component 9, C9 ELISA Kit
Brand: CUSABIO
SKU: CSB-E14011h

Promotion

Code: CSB-E14011h

Rate （N/A）
Review （0）

Compare

Size:

96T,5×96T,10×96T

Pls inquire

Quantity:

Sample Types: serum, plasma, urine

Detect Range: 10.97 pg/mL-8000 pg/mL

Sensitivity: 10.97 pg/mL

Trial Size:

24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >>

Interested in a trial size? Please leave a message below.

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Promotion

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Target Name

complement component 9

Alternative Names

C9; Complement component C9

Abbreviation

Uniprot NO.

P02748

Species

Homo sapiens (Human)

Sample Type

serum, plasma, urine

Detection Range

10.97 pg/mL-8000 pg/mL

Sensitivity

10.97 pg/mL

Assay Time

1-5h

Sample Loading Volume

50-100ul

Detection Wavelength

450 nm

Research Area

Immunology

Assay Principle

quantitative
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.

Measurement

Sandwich

Storage

Store at 2-8°C. Please refer to protocol.

Shelf Life

6 months

Lead Time

3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Precision

Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of human C9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
	Sample	Serum(n=4)
1:2000	Average %	96
	Range %	90-104
1:4000	Average %	91
	Range %	87-98
1:8000	Average %	95
	Range %	90-110
1:16000	Average %	96
	Range %	89-100

Recovery

The recovery of human C9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type	Average % Recovery	Range
Serum (n=5)	96	92-101
EDTA plasma (n=4)	97	87-106

Typical Data

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

pg/ml	OD1	OD2	Average	Corrected
8000	2.577	2.514	2.546	2.455
2666.7	1.845	1.864	1.855	1.764
888.9	1.239	1.213	1.226	1.135
296.3	0.851	0.844	0.848	0.757
98.8	0.388	0.399	0.394	0.303
32.9	0.214	0.207	0.211	0.120
10.97	0.139	0.142	0.141	0.050
0	0.089	0.093	0.091

Troubleshooting and FAQs

ELISA kit FAQs

ELISA Data Analysis

ELISA Standard Curve & Curve Expert software

Images

Human Complement Component 9, C9 ELISA Kit

Description

This Human complement component 9 ELISA Kit was designed for the quantitative measurement of Human complement component 9 protein in serum, plasma, urine. It is a Sandwich ELISA kit, its detection range is 10.97 pg/mL-8000 pg/mL and the sensitivity is 10.97 pg/mL.

■ Customer Reviews

Submit a Review here

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

Function(From Uniprot)

Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.

Gene References into Functions

The data supports the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in retinal pigment epithelial cells. PMID:30090015
Serum-expressed apolipoprotein B-100 protein, C9 Complement, and gelsolin can be used for differential diagnosis of Barrertts esophagus and adenocarcinoma of esophagus. PMID:26404905
Data indicate that complement C9 binds to the ATPase domain of mortalin. PMID:24719326
Liver biopsy specimens from chronically hepatitis C virus-infected patients exhibited a lower level of C9 mRNA expression than liver biopsy specimens from unrelated disease or healthy control human liver RNA. PMID:23487461
the haploinsufficiency of C9, a terminal complement complex component, engenders reduced intraocular secretion of VEGF and decreased risk for CNV development. PMID:22190594
C9 and fucosylated form could serve as a useful marker for SQLC. PMID:21840429
It was concluded that variations in the complement component 9 gene are unlikely to influence clearance of chronic hepatitis B virus infection and hepatocellular carcinoma occurrence. PMID:21380615
Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9. PMID:21507937
These results suggested that the lack of membrane attack complex because of an Arg95Stop mutation of the complement component 9 gene predisposed patients to pathognomonic glomerulonephritis. PMID:21057849
provided evidence for the recognition of membrane-bound C9 on complement-lysed ghosts by an antibody specific for the helix-turn-helix fold. PMID:20153530
Data show that mortalin supports cancer cell resistance to complement-dependent cytotoxicity and suggest consideration of mortalin as a novel target for cancer adjuvant immunotherapy. PMID:19739077
The human complement C9 gene: structural analysis of the 5' gene region and genetic polymorphism studies. PMID:11881818
C9 binding is dependent on the N-terminal modules (thrombospondin type 1 and low-density lipoprotein receptor class A) of C8 alpha together with the C8 alpha membrane attack complex/perforin domain. PMID:12463754
Founder effect was demonstrated for the R95X mutation of the C9 gene in Japanese PMID:12596049
results indicate that the principal binding site for C9 lies within the MACPF domain of C8alpha PMID:16618117
analysis of the CD59-C9 binding interaction PMID:16844690